242,110 Shares in Amedisys, Inc. (NASDAQ:AMED) Acquired by Calamos Advisors LLC

Calamos Advisors LLC purchased a new stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 242,110 shares of the health services provider's stock, valued at approximately $23,015,000. Calamos Advisors LLC owned 0.74% of Amedisys as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Amedisys by 3.7% during the 1st quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider's stock worth $671,378,000 after acquiring an additional 138,484 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Amedisys by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,241,160 shares of the health services provider's stock worth $302,724,000 after acquiring an additional 12,137 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Amedisys by 13.5% during the 1st quarter. JPMorgan Chase & Co. now owns 1,997,030 shares of the health services provider's stock worth $146,881,000 after acquiring an additional 237,160 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Amedisys by 3.5% during the 1st quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider's stock worth $323,092,000 after acquiring an additional 62,863 shares in the last quarter. Finally, Pentwater Capital Management LP boosted its stake in shares of Amedisys by 239.5% during the 3rd quarter. Pentwater Capital Management LP now owns 1,144,000 shares of the health services provider's stock worth $106,850,000 after acquiring an additional 807,000 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Stock Performance

AMED stock traded down $0.38 during trading on Friday, reaching $90.40. 384,903 shares of the stock were exchanged, compared to its average volume of 284,870. The company has a market capitalization of $2.95 billion, a P/E ratio of -291.61, a price-to-earnings-growth ratio of 4.28 and a beta of 0.86. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys, Inc. has a twelve month low of $73.10 and a twelve month high of $96.44. The stock has a 50 day simple moving average of $92.77 and a 200-day simple moving average of $93.41.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The health services provider reported $0.94 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.10). Amedisys had a positive return on equity of 12.76% and a negative net margin of 0.44%. The company had revenue of $570.79 million during the quarter, compared to the consensus estimate of $566.85 million. During the same quarter last year, the firm earned $1.16 EPS. The business's revenue for the quarter was up 1.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Amedisys, Inc. will post 4.54 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on AMED shares. StockNews.com assumed coverage on Amedisys in a research note on Monday, April 8th. They set a "buy" rating for the company. Royal Bank of Canada raised their target price on Amedisys from $97.00 to $100.00 and gave the stock an "outperform" rating in a research report on Monday, March 25th. Finally, Raymond James reaffirmed a "market perform" rating on shares of Amedisys in a research report on Tuesday, March 26th. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $97.50.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.